Ankylosing Spondylitis Transcriptomic Biomarkers and Drug Predictions

2026 research by Shuai Wang identifies candidate biomarkers and therapeutic targets for ankylosing spondylitis. The dataset contains results from transcriptomic profiling, Mendelian randomization analysis, and drug prediction, with findings validated by RT–qPCR on clinical blood samples. Specific genes RORA, FBXO31, and MSRB3 are highlighted as causally linked to disease risk.

Use Cases

• Validate the causal association of RORA, FBXO31, and MSRB3 expression with ankylosing spondylitis risk using Mendelian randomization results.
• Analyze correlations between identified gene biomarkers and immune cell infiltration profiles, such as Th1 cells and keratinocytes.
• Investigate predicted therapeutic agents like indirubin and pentoxifylline based on drug prediction analysis outputs.
• Explore functional enrichment results, such as involvement in olfactory transduction pathways, for biological interpretation.

Strengths

• Includes RT–qPCR validation on clinically collected blood samples, providing experimental support for computational findings.
• Applies multiple analytical methods: transcriptomics, Mendelian randomization, functional enrichment, immune infiltration, and drug prediction.
• Released under a permissive CC BY 4.0 license for broad reuse.

Limitations

• Dataset is very small at 10.3 KB, indicating limited raw data or summary-level results only.
• Unknown row and column counts prevent assessment of data volume and feature detail.
• Sample data and specific column structure are unavailable, complicating direct analytical reuse.

Provenance

Source

Shuai Wang via figshare.

Collection Method

Transcriptomic profiling of peripheral blood from AS patients, Mendelian randomization analysis, functional enrichment, immune infiltration analysis, drug prediction, and RT–qPCR validation.

Time Range

null

Freshness

Last updated March 2026.

Geography

null